Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Karam, Irene ^a,b   Hamilton, Sarah ^a,b   Nichol, Alan ^a,b   Woods, Ryan ^b   Speers, Caroline ^b   Kennecke, Hagen ^a,b   Tyldesley, Scott ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Brain irradiation; Brain metastasis; Breast cancer; HER2 status; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS;

EID: 84872018758     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-12     Document Type: Article

References (21)

1. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009, 27:5278-5286. 10.1200/JCO.2008.19.8481, 19770385.
2. Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'reilly SE, Olivotto IA. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007, 110:973-979. 10.1002/cncr.22867, 17647245.
3. Tsao MN, Lloyd NS, Wong RK, Rakovitch E, Chow E, Laperriere N, . Supportive Care Guidelines Group of Cancer Care Ontario's Program in Evidence-based Care Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2005, 31:256-273. 10.1016/j.ctrv.2005.04.007, 15951117, Supportive Care Guidelines Group of Cancer Care Ontario's Program in Evidence-based Care.
4. Tsao MN, Lloyd N, Wong R, Chow E, Rakovitch E, Laperriere N. Whole brain radiotherapy for the treatment of multiple brain metastases. Cochrane Database Syst Rev 2012, 4:CD003869.
5. Spector NL, Blackwell KL. Understanding the mechanisms behind Trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847. 10.1200/JCO.2009.22.1507, 19884552.
6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684. 10.1056/NEJMoa052122, 16236738.
7. Slamon D, Leyland-Jones B, Shak S, et al. Addition of herceptin [Superscript TM] (humazined anti-HER2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998, 17:98a.
8. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007, 13:1648-1655. 10.1158/1078-0432.CCR-06-2478, 17363517.
9. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500. 10.1056/NEJM199002223220802, 2405271.
10. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008, 26:5697-5704. 10.1200/JCO.2007.15.8659, 19001334.
11. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751. 10.1016/S0360-3016(96)00619-0, 9128946.
12. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006, 107:696-704. 10.1002/cncr.22041, 16826579.
13. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97:2972-2977. 10.1002/cncr.11436, 12784331.
14. Stemmler H, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008, 13:739-750. 10.1634/theoncologist.2008-0052, 18614587.
15. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer The importance of HER-2 status. Cancer 2008, 112:2359-2367. 10.1002/cncr.23468, 18361426.
16. Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 2012, 106:25-31. 10.1038/bjc.2011.531, 3251869, 22127284.
17. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastases. Cancer 1979, 44:1913-1918. 10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D, 498057.
18. Boogerd W, Vos VW, Hart AA, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 1993, 15:165-174. 10.1007/BF01053937, 8509821.
19. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008, 70:510-514. 10.1016/j.ijrobp.2007.06.074, 17931798.
20. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, Kirkpatrick J, Schwer A, Gaspar LE, Fiveash JB, Chiang V, Knisely J, Sperduto CM, Mehta M. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010, 77:655-661. 10.1016/j.ijrobp.2009.08.025, 19942357.
21. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012, 30:419-425. 10.1200/JCO.2011.38.0527, 3269967, 22203767.